Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

GLP-1 Receptor Agonists

Public_Health

Public Health Today—28 November, 2025

Explore this week’s public health highlights, including new developments,…

Obesity Weekly News

Obesity Weekly News - October 7th 2025

Obesity Update: MET-097i Breakthrough, New EASO Guidelines, & More! From…

Endocrinology

Endocrinology Weekly Update - September 29th 2025

Endocrinology Update: Once-Weekly Kyinsu, Bayer’s Lynkuet, EASD’s clinical…

Public_Health

Public Health Weekly News - September 19th 2025

Public Health Update: Lifestyle and Alzheimer’s, Stem Cells Post-Stroke,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Respiratory Video Recap—November 28, 2025
Vaccines Video Recap—November 28, 2025
Public Health Today—28 November, 2025

Tags

advanced therapies AI in dermatology Anti-Vaccine Movement antimicrobiotics pipeline bioinformatics cancer cisplatin ckd Colorectal Cancer competitive intellgence corporate venture capital Digital Inhaler dostarlimab drug pricing drug supply chain Elranatamab ESMO 2021 Galderma gene editing gene therapy approval HCPs hematology Immunoglobulin Replacement Therapy immunoglobulin treatments immunooncology India Pharma investment Longevity industry managed entry agreements Medical Affairs mRNA1345 mRNA technology mrna vaccines nanotechnology NFTs in healthcare non viral vectors oncology trials pharma pulmonary care remote patient monitoring Sema4 Share Of Voice T1D tissue engineering unconventional trial designs

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Respiratory Video Recap—November 28, 2025
Vaccines Video Recap—November 28, 2025
Public Health Today—28 November, 2025

TAGS

advanced therapies AI in dermatology Anti-Vaccine Movement antimicrobiotics pipeline bioinformatics cancer cisplatin ckd Colorectal Cancer competitive intellgence corporate venture capital Digital Inhaler dostarlimab drug pricing drug supply chain Elranatamab ESMO 2021 Galderma gene editing gene therapy approval HCPs hematology Immunoglobulin Replacement Therapy immunoglobulin treatments immunooncology India Pharma investment Longevity industry managed entry agreements Medical Affairs mRNA1345 mRNA technology mrna vaccines nanotechnology NFTs in healthcare non viral vectors oncology trials pharma pulmonary care remote patient monitoring Sema4 Share Of Voice T1D tissue engineering unconventional trial designs

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy